Stockscreener 앱 받기
4.34
1.59%
-0.07
시간 외 거래:
4.32
-0.02
-0.46%
전일 마감가:
$4.41
열려 있는:
$4.4
하루 거래량:
1.17M
Relative Volume:
0.56
시가총액:
$857.31M
수익:
$191.45M
순이익/손실:
$160.72M
주가수익비율:
5.2766
EPS:
0.8225
순현금흐름:
$-34.44M
1주 성능:
-0.91%
1개월 성능:
-9.58%
6개월 성능:
+5.08%
1년 성능:
+32.32%
1일 변동 폭
$4.27
$4.4495
1주일 범위
$4.26
$4.525
52주 변동 폭
$3.26
$5.38
Arbutus Biopharma Corp Stock (ABUS) Company Profile
명칭
Arbutus Biopharma Corp
전화
604-419-3200
주소
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.34 | 871.14M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-02-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 개시 | Jefferies | Hold |
| 2020-12-17 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 재개 | JMP Securities | Mkt Outperform |
| 2020-07-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-06 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 개시 | Robert W. Baird | Outperform |
| 2020-02-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 재확인 | B. Riley FBR | Buy |
| 2019-10-04 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2018-10-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-06 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 재개 | Chardan Capital Markets | Buy |
| 2018-03-19 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 재확인 | Wedbush | Outperform |
| 2016-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
모두보기
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Corp (ABUS) Cash Flow - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090 - TradingKey
Arbutus Biopharma Corp (ABUS) Balance Sheet - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.440|Chg%:+0.060 - TradingKey
TradingKey - TradingKey
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arbutus Biopharma Corp (ABUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arbutus Plans $230M Buyback as Patent Fight Expands - MyChesCo
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Arbutus Biopharma (ABUS) Files 8-K Announcing Agreement Termination and Key Company Details - Minichart
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus (ABUS) Plans Share Buyback Program Starting Q3 - GuruFocus
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus awards litigation bonuses to CEO Lindsay Androski; CFO Tuan Nguyen to receive discretionary bonus - TradingView
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback - Stock Titan
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks - Yahoo Finance
Arbutus Biopharma stock hits 52-week high at 5.34 USD - Investing.com UK
Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com - Investing.com South Africa
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Yahoo Finance
ABUS Stock Price, Quote & Chart - ChartMill
ABUSArbutus Biopharma Corp Options - Finviz
Gov't Says It Should Face Vax IP Claims, Not Moderna - Law360
Arbutus Biopharma Corp (ABUS) Institutional Confidence - TradingKey
Arbutus Biopharma Corp (ABUS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arbutus Biopharma (ABUS) Edges Higher on Improved Sentiment: Key Levels to WatchConversion Trade - DonanımHaber
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results - Insider Monkey
Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares - Stock Titan
Director at Arbutus Biopharma (ABUS) receives 78,800 fully vested stock options - Stock Titan
Arbutus Biopharma Holds Steady Near Midpoint of Trading RangeSymmetrical Triangle - dars.gov.et
Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case - Law360
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor - Stock Titan
Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
Arbutus Biopharma Corp (ABUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):